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HEALTH CARE RESOURCE UTILIZATION (HRU) AND DIRECT MEDICAL
EXPENDITURES (DME) FOR ADULT WOMEN WITH ANXIETY DISORDERS (AD) IN
THE UNITED STATES IN 2006 USING MEDICAL EXPENDITURES PANEL SURVEY
(MEPS)
Kavati A, Rappaport H
University of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVES: Estimate HRU and DME for adult women with AD.METHODS: A ret-
rospective cross-sectional case-control design using 2006 MEPS. Females  17
years who reported AD were selected. A control group was created using propen-
sity score matching. The data was fitted to poisson (P), negative binomial (NB),
zero-inflated poisson (ZIP), and zero-inflated negative binomial (ZINB) models. A
plot of residuals was examined and the plot closest to zero was selected as the best
fitting model. To calculate the HRU attributable to AD, the unadjusted mean num-
ber of visits for those without AD was multiplied by the regression coefficient for
AD from the multivariate regression minus the unadjusted mean number of visits
for those without AD. To estimate DME, a generalized linear model (GLM) was
estimated with a Park’s test to select the appropriate variance function after which
the incremental expenditurewas calculated by themethod of recycled predictions.
All analyses incorporated the MEPS sampling and variance adjustment weights to
ensure nationally representative sample. All the component expenditures were
summed and multiplied by the number of females who reported AD in 2006 to get
the national estimate of direct medical expenditures. RESULTS: The annual num-
ber of inpatient, emergency room, outpatient, and office based visits attributable to
ADwas 0.03, 0.07, 0.34, AND4.3 respectively. Therewere 0.05 homehealth days and
8.47 prescriptions including refills obtained by adult women with AD. The esti-
mated national annual direct COI associated with AD among adult women was
$26.52 billion. This was calculated bymultiplying the per-person total incremental
medical expenditure associated with AD among female adults ($2,143.16) with the
prevalence of AD (12,374,189). CONCLUSIONS: Inpatient expenditures accounted
for the largest proportion of DME followed by office based and prescription expen-
ditures. Adult women with AD have a significant societal burden.
PMH72
ANTIDEPRESSANT PERSISTENCE AND ASSOCIATED HEALTH CARE
EXPENDITURES IN CHILDREN WITH DEPRESSION
Karkare S1, Aparasu RR2, Chen H2, Rajan SS2
1Center for Medical Technology and Policy, Baltimore, MD, USA, 2University of Houston, Houston,
TX, USA
OBJECTIVES: The objectives of the study were to examine persistence and factors
associated with persistence to antidepressant medications in depressed children
and adolescents and to evaluate health care expenditures across persistent pa-
tients and non-persistent patients. METHODS: Medical Expenditure Panel Survey
(MEPS) data from the years 2002-2007 were used for the analysis. The study sample
consisted of depressed children and adolescents taking an antidepressant. Multi-
ple logistic regression analysis was conducted to examine factors associated with
persistence, after controlling for various independent variables like the predispos-
ing, enabling and need factors chosen on the basis of Anderson Behavioral Model,
and controls for year and timeframe. Linear regression models, containing log of
prescription drug expenditures and ambulatory expenditures as the dependent
variables, were used to evaluate the expenditures. Unweighted statistical analysis
was performed due to small sample cell size. RESULTS: Analytical sample con-
sisted of 281 children and adolescents using antidepressants. Approximately 53%
of the children and adolescents initiated on the antidepressant therapy were not
persistent. Social limitation was found to be a significant predictor increasing per-
sistence. Switching was prevalent in 16% of the children and adolescents. Analysis
of expenditures revealed that being persistent led to a 2.5 times increase in the
prescription drug expenditures, with no impact on ambulatory care expenditures.
CONCLUSIONS: Over half of the patients on antidepressant therapy were not persis-
tent. Although persistence of antidepressant therapy did not translate into reduction
in ambulatory expenditures, it may play a role in clinical and humanistic outcomes.
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RETROSPECTIVE ANALYSIS OF THE IMPACT OF PERSISTENCE ON HEALTH CARE
CHARGES AMONG OPIOID-DEPENDENT PATIENTS TREATED WITH
BUPRENORPHINE/NALOXONE USING AN INSURANCE DATABASE IN THE
UNITED STATES
Zah V1, Aballea S2, Guelfucci F3, Clay E3, Baxter T4
1ISPOR Serbia, Beograd, Serbia and Montenegro, 2Creativ Ceutical, Paris, Ile de France, France,
3Creativ Research, Paris, France, 4Reckitt Benckiser Pharmaceuticals Inc, Richmond, VA, USA
OBJECTIVES: Buprenorphine/naloxone (Suboxone®, Reckitt-Benckiser) is recom-
mended for treating opiate addiction. Clinical guidelines do not specify the mini-
mum duration of treatment required to achieve long-term remission. This study
evaluated the impact of persistence on resource utilisation andhealthcare charges.
METHODS: This retrospective study used a US insurance claims database. It in-
cluded patients with a BUP/NAL claim, not previously treated with buprenorphine,
with at least one repeat claim after 30 days. Discontinuation was defined as ab-
sence of BUP/NAL claim for 90 days. Healthcare charges over 12 months were
compared between persistent and non-persistent patients, adjusting on baseline
characteristics (demographics, comorbidities, treatment, and resource utilisation
before index date). Charges before and after discontinuation were compared using
generalized linear models with repeated observations. RESULTS: Of 6868 patients
with an incident claim of BUP/NAL, 42.4% appeared to be short-term users and
were excluded. Among the remaining 3955 patients, 1287 were followed for at least
one year. The Kaplan-Meier estimate of the probability of continuing treatment
over 12 months was 61.2%. No significant predictors of discontinuation were iden-
tified except age and initial dose. The 12-month persistent cohort had lower mean
total charges compared to non-persistent patients ($22,033 vs. $30,518; p0.0012
adjusting on baseline characteristics). Among non-persistent patients, total
charges reached a maximum during the first trimester following discontinuation
(63% compared to period from 6 to 4 months before discontinuation, p0.0001),
and were non-significantly higher in the second trimester after discontinuation
compared to before discontinuation. Main drivers of excess charges were hospital-
ization and outpatient visits. CONCLUSIONS: Among long-term users of BUP/NAL,
a substantial proportion discontinued treatment within 12 months. This analysis
showed that non-persistence was associated with higher charges and evidence
was consistent with a causal relationship between discontinuation and increased
charges. However, identifying causes of discontinuation and means to improve
persistence using claims data is challenging.
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UTILIZATION, PRICE AND SPENDING TRENDS FOR
SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS IN THE UNITED STATES
MEDICAID PROGRAM: 1991-2009
Isla A, Guo JJ, Lin AC, Kelton CM, Heaton PC
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: Serotonin–norepinephrine reuptake inhibitors (SNRIs), comprising
arelatively new class of antidepressant drugs, have multiple approved indication-
ssuch as major depressive disorder and fibromyalgia. The objectives of this study-
were to (1) describe the trends in drug utilization, spending, and price for the
U.S.Medicaid program and (2) analyze the change in SNRI market share in the
marketfor all antidepressants, including as well selective serotonin reuptake in-
hibitors andtricyclic antidepressants.METHODS:A retrospective, descriptive anal-
ysis was performed using the national Medicaid pharmacy claims database, which
has information on outpatient prescription claims. Quarterly prescription counts
and reimbursement amounts were calculated for each of the SNRIs (branded or
generic) reimbursed by Medicaid from 1994 quarter 1 through 2009 quarter 4. Av-
erage per-prescriptions pending (implicit price) was found by dividing reimburse-
ment by the number of prescriptions. RESULTS: Until 2009, venlafaxine was the
most prescribed SNRI at which time it was topped in utilization by duloxetine. In
2009, Medicaid spent $159million and $169million for venlafaxine and duloxetine,
respectively, for 1.00 and 1.07 million prescriptions. The price of venlafaxine has
increased over time (the price in 2009 was almost 3 times the price in 1998). Utili-
zation of the new extended-release formulation of venlafaxine (Effexor XR®) has
risen exponentially, and this new formulationwas 8 timesmore prescribed than its
predecessor in 2009. After 2008, two new SNRIs (Pristiq® and Savella®) were mar-
keted, but their market shares were still very small at the end of 2009. In total,
Medicaid spent $342 million for 2.20 million prescriptions for SNRIs in 2009. The
SNRIs as a class represented 20% of total Medicaid reimbursement for antidepres-
sants at the end of 2009. CONCLUSIONS: Increased utilization may be due to mul-
tiple approved indications. Very little price competition is observed between
brands or between brand andgeneric venlafaxine.
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PSYCHIATRIC MORBIDITY AND BURNOUT AMONG HOSPITAL PHYSICIANS AND
NURSES: ASSOCIATION WITH PERCEIVED JOB-RELATED FACTORS
Tabolli S, di Pietro C, Renzi C
IDI IRCCS, Rome, Italy
OBJECTIVES: To evaluate psychiatric morbidity and burnout among physicians
and nurses of a general hospital in central Italy, examining the association with
perceived job-related factors.METHODS:Anonymous questionnaires were distrib-
uted to all 323 hospital physicians and 609 nurses of a non-profit health organisa-
tion in Rome, Italy. Standardised instruments were used to evaluate psychiatric
morbidity (General Health Questionnaire), burnout (Maslach Burnout Inventory)
andperceived job-related factors. Stepwise logistic regressionwas used to examine
the association between job-related factors, psychiatric morbidity and burnout,
controlling for demographic factors. RESULTS: Questionnaires were returned by
155 physicians and 216 nurses (overall response rate 40%). Estimated prevalence of
psychiatric morbidity was 25% among physicians and 36.9% among nurses. Burn-
out on the emotional exhaustion scale affected 38.7% of physicians and 46.4% of
nurses. Personnel with emotional exhaustion was at higher risk of psychiatric
morbidity (p0.001). The likelihood of psychiatricmorbidity among physicianswas
increased by perceived insufficient recognition of personal commitments by the
unit’s head (OR4.21; 95%CI 1.2-15.1; p0.027), insufficient managerial ability of
the unit’s head (OR3.45; 95%CI 1.2-10.1; p0.023), unsatisfactory communication
(OR5.30;95%CI 1.6-17.6; p0.006). Among nurses, psychiatric morbidity was asso-
ciated with insufficient ability of the unit’s head to solve conflicts, insufficient
decisional power in relation to responsibilities, insufficient economic rewards and
career possibilities, working in surgery. Similar job-related factors were associated
also with emotional exhaustion. CONCLUSIONS: Psychiatric morbidity and burn-
out were relatively high, particularly among nurses. Specific job-related factors
were associated with psychiatric morbidity and burnout. Improving these aspects
is important for the well-being of hospital staff and the quality of patient care.
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PHARMACIST AND PHARMACY STAFF KNOWLEDGE AND ATTITUDES
TOWARDS SUICIDE AND SUICIDE PREVENTION AFTER A NATIONAL VA
TRAINING PROGRAM
Lavigne JE, King DA, Lu N, Knox KL, Kemp JE
U.S. Department of Veterans Health Affairs, Canandaigua, NY, USA
OBJECTIVES: To evaluate US Department of Veterans Affairs (VA) training in sui-
cide prevention on pharmacists’ and pharmacy staff’s knowledge of and attitudes
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